|  |
| |
| Figure 2. A. Schematic representation of human PRLR variants. Forms generated by alternative splicing. B. Structure of human prolactin receptor variants. Receptor structure of the various forms. LF: long form; IF: intermediate form; S: short forms; 10': partial exon 10; Δ#: deleted exon; #/#: exon/exon splice variant; D1, D2: N-terminal subdomain; WS: WSXWS motif; C: cysteine; Y: tyrosine; EC: extracellular domain; TM: transmembrane domain; IC: intracellular domain. Blue boxes (dark and light) in IC represent two unique sequences of short forms derived from exon 11. Amino acid number includes the signal peptide. |
| |
Description | Several forms of the human prolactin receptor have been identified including the full length activating receptor (LF) and at least eight other variants (figures 2A and 2B). These variants differ by the length and composition of their extracellular and/or cytoplasmic domain. In addition to the membrane anchored prolactin receptors variants there is a soluble isoform (prolactin receptor binding protein -PRLRBP) that is generated by proteolytic cleavage of membrane bound prolactin receptor. The human prolactin receptor is composed of a single transmembrane domain, a ligand binding extracellular domain and a cytoplasmic domain which is required for signal transduction. Two disulfide-linked cysteines in the D1 subdomain are involved in ligand binding while WSXWS motif in the D2 subdomain is probably required for correct folding and cellular trafficking. Box 1, a proline rich domain highly conserved in the cytokine receptor family, is the JAK2 docking site. The activated JAK2 induced by prolactin (autophosphorylation), phosphorylates the dimerized receptor preferentially Y587 (at a consensus tyrosine phosphorylation site) which is only present in LF and ΔS1 (figure 2A). This is followed by phosphorylation, dimerization and nuclear translocation of STAT5 which causes transcriptional activation of prolactin responsive genes (i.e. β-casein, β-lactoglobulin, whey acidic protein, interferon-regulatory factor 1 and others). There are other nine tyrosines in the cytoplasmic domain (non-consensus phosphorylation sites) some of which may undergo phosphorylation and may participate in signal transduction. Box2 of unknown function is less conserved in the cytokine receptor family. Prolactin can also activate other tyrosine kinases, including Src family kinases, focal adhesion proteins, Tec kinase, and ErbB kinase. Prolactin induces the GRB2/SOS/Ras/Raf/MAPK signaling cascade. Prolactin through the long form of the receptor stimulates cell proliferation. The Δ-S1 form lacking exon 4 and 5, has reduced affinity for the hormone (due to abbreviated extracellular domain) but displays effective signal transduction. Stimulation of the intermediate form of the receptor (major deletion of exon 10, cytoplasmic domain) only with high concentrations of the ligand exhibits minor cell proliferation. The short forms of the receptor S1a and S1b derived from alternative splicing of exons 10 and 11 are inhibitory of the activation induced by prolactin through the long form of the receptor (see above). Intramolecular disulfide bonds of the prolactin receptor short form are required from its inhibitory action on the function of the long form of the receptor. Δ7/11 and Δ4-Δ7/11 isoforms do not contain transmembrane domain. Δ7/11, Δ4-Δ7/11 and PRLBP are soluble prolactin receptor. Δ4/6 S1a (Acc#. AF512796) variant encodes two open reading frames either 245 or 49 aa truncated prolactin receptor. Spliced variant S1c missing exon 10 was identified in spermatozoa (Acc#. GU133399). |
Expression | Prolactin receptors have been identified in number of cells and tissues including the mammary gland, organs of the reproductive system, central nervous system, pituitary, adrenal cortex, skin, bone, lung, heart, liver, pancreas, GI tract, kidney, lymphoid tissue and spermatozoa. These are also present in breast cancer tissues and cells and in other tumoral tissues/cells. |
Localisation | Localized in the cell membrane, but also present intracellularly at various compartments. |
Function | The prolactin receptor mediates prolactin signaling and triggers intracellular responses that participate in diverse biological functions including, mammary gland development (proliferation and differentiation), initiation and maintenance of lactation, regulation of water and salt balance, reproduction, gonadal steroidogenesis, preservation of sperm integrity, embryonic implantation, brain and behavior, and immune-regulation (see description). |
Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. |
Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P; Benign Breast Diseases Study Group. |
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14533-8. Epub 2008 Sep 8. |
PMID 18779591 |
|
Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. |
Boutin JM, Edery M, Shirota M, Jolicoeur C, Lesueur L, Ali S, Gould D, Djiane J, Kelly PA. |
Mol Endocrinol. 1989 Sep;3(9):1455-61. |
PMID 2558309 |
|
Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma? |
Canbay E, Degerli N, Gulluoglu BM, Kaya H, Sen M, Bardakci F. |
Curr Med Res Opin. 2004 Apr;20(4):533-40. |
PMID 15119991 |
|
Presence and characterization of prolactin receptors in human benign breast tumours. |
Di Carlo R, Muccioli G, Bellussi G, Lando D, Mussa A. |
Eur J Cancer Clin Oncol. 1984 May;20(5):635-8. |
PMID 6145592 |
|
A novel estradiol/estrogen receptor alpha-dependent transcriptional mechanism controls expression of the human prolactin receptor. |
Dong J, Tsai-Morris CH, Dufau ML. |
J Biol Chem. 2006 Jul 7;281(27):18825-36. Epub 2006 May 1. |
PMID 16651265 |
|
Absence of prolactin receptors in normal and malignant uterine cervix. |
Dowsett M, McGarrick GE, Staffurth J, Worth RW, Chapman MG, Jeffcoate SL. |
Br J Obstet Gynaecol. 1984 Sep;91(9):924-6. |
PMID 6089861 |
|
Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. |
Gill S, Peston D, Vonderhaar BK, Shousha S. |
J Clin Pathol. 2001 Dec;54(12):956-60. |
PMID 11729217 |
|
Identification of gain-of-function variants of the human prolactin receptor. |
Goffin V, Bogorad RL, Touraine P. |
Methods Enzymol. 2010;484:329-55. |
PMID 21036240 |
|
Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. |
Hu ZZ, Meng J, Dufau ML. |
J Biol Chem. 2001 Nov 2;276(44):41086-94. Epub 2001 Aug 22. |
PMID 11518703 |
|
Complex 5' genomic structure of the human prolactin receptor: multiple alternative exons 1 and promoter utilization. |
Hu ZZ, Zhuang L, Meng J, Tsai-Morris CH, Dufau ML. |
Endocrinology. 2002 Jun;143(6):2139-42. |
PMID 12021177 |
|
Complex formation and interactions between transcription factors essential for human prolactin receptor gene transcription. |
Kang JH, Tsai-Morris CH, Dufau ML. |
Mol Cell Biol. 2011 Aug;31(16):3208-22. Epub 2011 Jun 13. |
PMID 21670145 |
|
Functional characterization of the intermediate isoform of the human prolactin receptor. |
Kline JB, Roehrs H, Clevenger CV. |
J Biol Chem. 1999 Dec 10;274(50):35461-8. |
PMID 10585417 |
|
Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain. |
Kline JB, Rycyzyn MA, Clevenger CV. |
Mol Endocrinol. 2002 Oct;16(10):2310-22. |
PMID 12351696 |
|
Characterization and modulation of a prolactin receptor mRNA isoform in normal and tumoral human breast tissues. |
Laud K, Gourdou I, Belair L, Peyrat JP, Djiane J. |
Int J Cancer. 2000 Mar 15;85(6):771-6. |
PMID 10709093 |
|
Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. |
Mellai M, Giordano M, D'Alfonso S, Marchini M, Scorza R, Giovanna Danieli M, Leone M, Ferro I, Liguori M, Trojano M, Ballerini C, Massacesi L, Cannoni S, Bomprezzi R, Momigliano-Richiardi P. |
Hum Immunol. 2003 Feb;64(2):274-84. |
PMID 12559630 |
|
Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma. |
Meng J, Tsai-Morris CH, Dufau ML. |
Cancer Res. 2004 Aug 15;64(16):5677-82. |
PMID 15313907 |
|
Prolactin exerts a prosurvival effect on human spermatozoa via mechanisms that involve the stimulation of Akt phosphorylation and suppression of caspase activation and capacitation. |
Pujianto DA, Curry BJ, Aitken RJ. |
Endocrinology. 2010 Mar;151(3):1269-79. Epub 2009 Dec 23. |
PMID 20032052 |
|
Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. |
Qazi AM, Tsai-Morris CH, Dufau ML. |
Mol Endocrinol. 2006 Aug;20(8):1912-23. Epub 2006 Mar 23. |
PMID 16556730 |
|
Short form 1b human prolactin receptor down-regulates expression of the long form. |
Tan D, Walker AM. |
J Mol Endocrinol. 2010 Mar;44(3):187-94. Epub 2009 Nov 11. |
PMID 19906835 |
|
Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. |
Trott JF, Hovey RC, Koduri S, Vonderhaar BK. |
J Mol Endocrinol. 2003 Feb;30(1):31-47. |
PMID 12580759 |
|
Intramolecular disulfide bonds of the prolactin receptor short form are required for its inhibitory action on the function of the long form of the receptor. |
Xie YL, Hassan SA, Qazi AM, Tsai-Morris CH, Dufau ML. |
Mol Cell Biol. 2009 May;29(10):2546-55. Epub 2009 Mar 9. |
PMID 19273600 |
|